Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
Disclosure of interest: None Poster Session II - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.02 - ACUTE MANAGEMENT - Thrombolysis or thrombectomy P682 - ESOC25-1141 RISK OF SYMPTOMATIC INTRACRANIAL HEMORRHAGE IN ENDOVASCULAR STROKE TREATMENT: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Joo Andr Sousa 1 , Sara Bernardo-Castro 2 , Joao Nuno Ramos 3 , Helena Donato 4 , Joo Sargento Freitas 1 1 Stroke Unit, Unidade Local de Sade de Coimbra, Portugal, Coimbra, Portugal, 2 IISPV Pere Virgili Health Research Institute, Tarragona, Spain, 3 Diagnostic Neuroradiology Unit, Imaging Department, Unidade Local de Sade Gaia e Espinho, Vila Nova de Gaia, Portugal, Vila Nova de Gaia, Portugal, 4 Documentation and Scientific Information Service, Hospitais da Universidade de Coimbra, Unidade Local de Sade de Coimbra, Portugal, Coimbra, Portugal Background and Aims: Symptomatic intracranial hemorrhage (sICH) is a key safety outcome in endovascular therapy (EVT) for acute ischemic stroke (AIS)
The maintenance dose is usually about 24 g/day, adjusted based on kidney function
Why Choose Peptides
FAQs What is the difference between bacteriostatic water and sterile reconstitution solution
